Immunochemotherapy with levamisole for stage III gastric cancer patients.
Levamisole (LMS) was given to stage III gastric cancer patients starting three days before gastrectomy, at a does of 150 mg/day for three consecutive days every other week. Survival rates of these patients were compared with those of stage III gastric cancer patients previously operated in our Department who had not received levamisole. The background factors of both groups were matched as closely as possible. Both groups were concomitantly treated with mitomycin C and FT-207. The survival rate of the LMS group was significantly higher than that of the control group when the tumor had a diameter of 4.0-8.0 cm, cancer cells infiltrated to the gastric serosa, there were metastases within the regional lymph nodes, cancer cells slightly invaded the venous capillaren and there was moderate infiltration of the stroma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007223:Infant; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011300:Preoperative Care; D013274:Stomach Neoplasms / Q000401:mortality / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage
D008937:Mitomycins; D005641:Tegafur; D007978:Levamisole; D016685:Mitomycin